Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 245 | 36 | 203 |
| Samples | 224 | 35 | 183 |
| Peptides | 153 | 25 | 130 |
Function
KRT81 · Keratin 81
The protein encoded by this gene is a member of the keratin gene family. As a type II hair keratin, it is a basic protein which heterodimerizes with type I keratins to form hair and nails. The type II hair keratins are clustered in a region of chromosome 12q13 and are grouped into two distinct subfamilies based on structure similarity. One subfamily, consisting of KRTHB1, KRTHB3, and KRTHB6, is highly related. The other less-related subfamily includes KRTHB2, KRTHB4, and KRTHB5. All hair keratins are expressed in the hair follicle; this hair keratin, as well as KRTHB3 and KRTHB6, is found primarily in the hair cortex. Mutations in this gene and KRTHB6 have been observed in patients with a rare dominant hair disease, monilethrix. Some human genome assemblies (example T2T-CHM13) have a non-coding version of the gene due to the presence of a SNP that introduces a premature stop codon after codon 281. [provided by RefSeq, Jan 2024].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000327741 | Q14533 | 245 | 153 |
Gene Properties
Recurrent Mutations
All 153 amino-acid changes on canonical ENST00000327741 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRT81 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRT81 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 9/612 1% |
| Melanoma | 3/210 1% | 27/1899 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Gastric Carcinoma | 2/74 3% | 18/1809 1% |
| Other Solid Cancers | 1/94 1% | 12/1515 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 6/810 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 11/1592 1% |
| Neuroendocrine Tumour | 2/154 1% | 3/577 1% |
| Colorectal Carcinoma | 2/143 1% | 21/3239 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 6/950 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 6/1611 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 7/2550 0% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 2/1390 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Glioma | 1/52 2% | 5/2127 0% |
| B-Lymphoblastic Leukemia | 5/55 9% | 1/2640 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 2/2534 0% |
| Other Blood Cancers | 0/61 0% | 5/2725 0% |
| Breast Carcinoma | 1/144 1% | 4/3264 0% |
Mutation Distribution
Where KRT81 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRT81 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 245 mutations in KRT81
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|